Shu Ruming, He Jie, Wu Chengzhen, Gao Jun
Department of Gynaecology and Obstetrics, The Third Affiliated Hospital of Nanchang University, Nanchang, China.
Tumour Biol. 2017 Jun;39(6):1010428317709126. doi: 10.1177/1010428317709126.
The RARβ and FHIT promoter methylation are observed in some cervical carcinoma. However, the association between RARβ and FHIT promoter methylation and cervical carcinogenesis remains unclear. This study was carried out to evaluate the correlation between RARβ or FHIT promoter methylation and cervical carcinogenesis. Eligible publications were searched via online databases. The combined odds ratios and corresponding 95% confidence intervals were calculated and summarized. In all, 17 eligible articles on RARβ and FHIT promoter methylation were identified in the study. RARβ promoter methylation was significantly higher in cervical cancer than in cervical intraepithelial neoplasia lesions and normal cervical tissues (odds ratio = 3.90, p = 0.018; odds ratio = 12.98, p < 0.001, respectively). There was more FHIT promoter methylation in cervical cancer than in cervical intraepithelial neoplasia lesions and normal controls (odds ratio = 8.0, p = 0.055; odds ratio = 10.75, p < 0.001, respectively). In addition, FHIT promoter methylation was correlated with clinical stage (advanced stage vs early stage: odds ratio = 2.69, p = 0.056) and tumor grade (high grade vs low grade: odds ratio = 4.11, p < 0.001). RARβ and FHIT promoter methylation may be associated with the carcinogenesis of cervical cancer. FHIT promoter methylation may play a crucial role in cervical cancer progression. Additional studies with large sample sizes are essential to confirm our findings.
在一些宫颈癌中观察到RARβ和FHIT启动子甲基化。然而,RARβ和FHIT启动子甲基化与宫颈癌发生之间的关联仍不清楚。本研究旨在评估RARβ或FHIT启动子甲基化与宫颈癌发生之间的相关性。通过在线数据库检索符合条件的出版物。计算并汇总合并比值比及相应的95%置信区间。本研究共纳入17篇关于RARβ和FHIT启动子甲基化的合格文章。宫颈癌中RARβ启动子甲基化显著高于宫颈上皮内瘤变病变和正常宫颈组织(比值比分别为3.90,p = 0.018;比值比为12.98,p < 0.001)。宫颈癌中FHIT启动子甲基化多于宫颈上皮内瘤变病变和正常对照(比值比分别为8.0,p = 0.055;比值比为10.75,p < 0.001)。此外,FHIT启动子甲基化与临床分期(晚期vs早期:比值比 = 2.69,p = 0.056)和肿瘤分级(高级别vs低级别:比值比 = 4.11,p < 0.001)相关。RARβ和FHIT启动子甲基化可能与宫颈癌的发生有关。FHIT启动子甲基化可能在宫颈癌进展中起关键作用。需要更多大样本研究来证实我们的发现。